Literature DB >> 8660841

An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells. Introduction of gamma c chain in RCC cells does not improve sensitivity.

R K Puri1, P Leland, N I Obiri, S R Husain, J Mule, I Pastan, R J Kreitman.   

Abstract

We have previously demonstrated that a chimeric protein composed of human IL-4 and Pseudomonas exotoxin, termed IL4-PE4E, is cytotoxic to primary cells derived from human renal cell carcinoma (RCC). To improve the cytotoxicity of IL4-toxins such as IL4-PE4E and IL4-PE38KDEL to IL-4 receptor (IL-4R) positive tumor cells, a circularly permuted chimeric toxin was prepared by fusing a truncated PE gene encoding PE38KDEL 3' to a circularly permuted IL-4 mutant gene encoding IL4 amino acids 38-129, the linker GGNGG, and IL4 amino acids 1-37. The resulting chimeric protein, termed IL4(38-37)-PE38KDEL, was tested on five RCC cell lines and its cytotoxicity was compared to that of the native IL4-toxins IL4-PE4E and IL4-PE38KDEL. IL4(38-37)-PE38KDEL was found to be 5 to 10 times more cytotoxic to all cell cultures tested compared to either native IL4-toxin. The cytotoxic activity of IL4(38-37)-PE38KDEL was competible by excess IL-4 and was confirmed by clonogenic assay. IL4(38-37)-PE38KDEL bound to IL-4R on RCC cells with 6- to 12-fold higher affinity than IL4-PE38KDEL or IL4-PE4E. RCC tumor cells were found to lack the common gamma chain (gamma c) of the IL-4R reported to be present on immune cells. The stable transfection of RCC cells with the gamma c chain gene did not significantly change their sensitivity to IL4(38-37)-PE38KDEL. Taken together, our results indicate that the CPIL4-toxin IL4(38-37)-PE38KDEL is highly cytotoxic to human RCC cells due to increased binding affinity to IL-4R while it is not cytotoxic or slightly cytotoxic to T and B cells, monocytic cell lines, and fresh resting or activated bone marrow-derived cells. The gamma c does not seem to increase the internalization rate and/or processing of IL4-toxins in RCC cells. CPIL4-toxin may be a useful agent for the treatment of human RCC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8660841     DOI: 10.1006/cimm.1996.0176

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.178


  6 in total

1.  Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin.

Authors:  S R Husain; P Gill; R J Kreitman; I Pastan; R K Puri
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

2.  Kinetic analysis of high affinity forms of interleukin (IL)-13 receptors: suppression of IL-13 binding by IL-2 receptor gamma chain.

Authors:  V A Kuznetsov; R K Puri
Journal:  Biophys J       Date:  1999-07       Impact factor: 4.033

3.  Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma.

Authors:  Friedrich Weber; Anthony Asher; Richard Bucholz; Mitchel Berger; Michael Prados; Susan Chang; Jeffrey Bruce; Walter Hall; Nikolai G Rainov; Manfred Westphal; Ronald E Warnick; Robert W Rand; Frank Floeth; Frank Rommel; Henry Pan; Vijay N Hingorani; Raj K Puri
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

4.  IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein.

Authors:  B H Joshi; P Leland; J Silber; R J Kreitman; I Pastan; M Berger; R K Puri
Journal:  Br J Cancer       Date:  2002-01-21       Impact factor: 9.075

5.  Interleukin-4 receptor alpha overexpression in human bladder cancer correlates with the pathological grade and stage of the disease.

Authors:  Bharat H Joshi; Pamela Leland; Samir Lababidi; Frederick Varrichio; Raj K Puri
Journal:  Cancer Med       Date:  2014-09-10       Impact factor: 4.452

6.  Therapeutic Effect of IL-4 Receptor-Targeting Pro-Apoptotic Peptide (AP1-ELP-KLAK) in Glioblastoma Tumor Model.

Authors:  Vijaya Sarangthem; Aena Yi; Yunjae Kim; Alnawaz Rehemtulla; Byung-Heon Lee; Young Hyun Jeon; Thoudam Debraj Singh; Rang-Woon Park
Journal:  Int J Nanomedicine       Date:  2021-07-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.